Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 4 (2007), Issue 6 (June)

1. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
   J Zhejiang Univ Sci B, 8(5): 307-13. [Abstract] [Full-text]
2. Supradiaphragmatic ectopic liver: delayed traumatic hepatic hernia mimics pulmonary tumor.
   Thorac Cardiovasc Surg, 55(4): 277-8. [Abstract] [Full-text]
3. Synchronous thymoma and lung carcinoma resected via median sternotomy with VATS guidance.
   Thorac Cardiovasc Surg, 55(4): 271-2. [Abstract] [Full-text]
4. Prediction of cardiopulmonary morbidity after resection for lung cancer: stair climbing test complications after lung cancer surgery.
   Thorac Cardiovasc Surg, 55(4): 253-6. [Abstract] [Full-text]
5. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
   J Thorac Oncol, 2(6): 571-3. [Abstract] [Full-text]
6. Controversy about small peripheral lung adenocarcinomas: how should we manage them?
   J Thorac Oncol, 2(6): 546-52. [Abstract] [Full-text]
7. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
   J Thorac Oncol, 2(6): 537-43. [Abstract] [Full-text]
8. Patterns of radiotherapy re-treatment in patients with lung cancer: a retrospective, longitudinal study.
   J Thorac Oncol, 2(6): 531-6. [Abstract] [Full-text]
9. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
   J Thorac Oncol, 2(6): 526-30. [Abstract] [Full-text]
10. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
    J Thorac Oncol, 2(6): 520-5. [Abstract] [Full-text]
11. The difficulties of a randomized study in superior vena caval obstruction.
    J Thorac Oncol, 2(6): 514-9. [Abstract] [Full-text]
12. Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: review of a single institution's experience.
    J Thorac Oncol, 2(6): 506-13. [Abstract] [Full-text]
13. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
    J Thorac Oncol, 2(6): 499-505. [Abstract] [Full-text]
14. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
    J Thorac Oncol, 2(6): 494-8. [Abstract] [Full-text]
15. Lung cancer in New Zealand: patterns of secondary care and implications for survival.
    J Thorac Oncol, 2(6): 481-93. [Abstract] [Full-text]
16. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
    J Thorac Oncol, 2(6): 475-80. [Abstract] [Full-text]
17. Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997.
    J Thorac Oncol, 2(6): 466-74. [Abstract] [Full-text]
18. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Int J Radiat Oncol Biol Phys, 68(3): 779-85. [Abstract] [Full-text]
19. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
    Int J Radiat Oncol Biol Phys, 68(3): 771-8. [Abstract] [Full-text]
20. A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors.
    Int J Radiat Oncol Biol Phys, 68(3): 839-44. [Abstract] [Full-text]
21. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
    Int J Radiat Oncol Biol Phys, 68(3): 786-93. [Abstract] [Full-text]
22. Acute L-glutamine deprivation compromises VEGF-a upregulation in A549/8 human carcinoma cells.
    J Cell Physiol, 212(2): 463-72. [Abstract] [Full-text]
23. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study.
    Cell Biol Int, 31(9): 1069-71. [Abstract] [Full-text]
24. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
    Am J Clin Oncol, 30(3): 258-63. [Abstract] [Full-text]
25. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Am J Clin Oncol, 30(3): 245-51. [Abstract] [Full-text]
26. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
    Am J Clin Oncol, 30(3): 239-44. [Abstract] [Full-text]
27. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
    J Natl Cancer Inst, 99(11): 858-67. [Abstract] [Full-text]
28. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
    J Natl Cancer Inst, 99(11): 847-57. [Abstract] [Full-text]
29. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
    J Natl Cancer Inst, 99(11): 838-46. [Abstract] [Full-text]
30. Occupation and risk of lung cancer in Central and Eastern Europe: the IARC multi-center case-control study.
    Cancer Causes Control, 18(6): 645-54. [Abstract] [Full-text]
31. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression.
    Oncogene, 26(27): 3989-97. [Abstract] [Full-text]
32. HIV infection is associated with an increased risk for lung cancer, independent of smoking.
    Clin Infect Dis, 45(1): 103-10. [Abstract] [Full-text]
33. Topotecan for the treatment of small-cell lung cancer.
    Expert Rev Anticancer Ther, 7(6): 795-801. [Abstract] [Full-text]
34. Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.
    J Clin Oncol, 25(17): 2377-82. [Abstract] [Full-text]
35. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.
    Lancet, 369(9577): 1929-37. [Abstract] [Full-text]
36. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.
    Cancer, 109(12): 2522-31. [Abstract] [Full-text]
37. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Cancer, 109(12): 2506-14. [Abstract] [Full-text]
38. Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells.
    Cancer Chemother Pharmacol, 60(3): 449-57. [Abstract] [Full-text]
39. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
    Invest New Drugs, 25(4): 351-5. [Abstract] [Full-text]
40. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
    Invest New Drugs, 25(4): 377-83. [Abstract] [Full-text]
41. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides.
    Nanomedicine, 3(2): 132-7. [Abstract] [Full-text]
42. Cell selective response to gold nanoparticles.
    Nanomedicine, 3(2): 111-9. [Abstract] [Full-text]
43. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study.
    Lancet, 369(9578): 2010-4. [Abstract] [Full-text]
44. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study.
    Lancet, 369(9578): 2015-20. [Abstract] [Full-text]
45. Effect of KAI1/CD82 on the beta1 integrin maturation in highly migratory carcinoma cells.
    Biochem Biophys Res Commun, 359(3): 703-8. [Abstract] [Full-text]
46. Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 104(1): 76-81. [Abstract] [Full-text]
47. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer.
    J Clin Oncol, 25(18): 2534-9. [Abstract] [Full-text]
48. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
    J Clin Oncol, 25(18): 2528-33. [Abstract] [Full-text]
49. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water.
    J Natl Cancer Inst, 99(12): 920-8. [Abstract] [Full-text]
50. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
    Am J Clin Pathol, 128(1): 100-8. [Abstract] [Full-text]
51. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series.
    Ann Thorac Surg, 84(1): 324-38. [Abstract] [Full-text]
52. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer.
    Ann Thorac Surg, 84(1): 203-10. [Abstract] [Full-text]
53. Influence of preoperative exercise capacity on length of stay after thoracic cancer surgery.
    Ann Thorac Surg, 84(1): 197-202. [Abstract] [Full-text]
54. Video-assisted thoracic surgery lobectomy with bronchoplasty for lung cancer: initial experience and techniques.
    Ann Thorac Surg, 84(1): 191-5. [Abstract] [Full-text]
55. Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer.
    Ann Thorac Surg, 84(1): 182-8; discussion 189-90. [Abstract] [Full-text]
56. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer.
    Ann Thorac Surg, 84(1): 177-81. [Abstract] [Full-text]
57. Induction of lung lesions in Wistar rats by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by aspirin and phenethyl isothiocyanate.
    BMC Cancer, 7: 90. [Abstract] [Full-text]
58. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
    Oncogene, 26(30): 4394-403. [Abstract] [Full-text]
59. FRMD3, a novel putative tumour suppressor in NSCLC.
    Oncogene, 26(30): 4464-8. [Abstract] [Full-text]
60. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg, 134(1): 188-93. [Abstract] [Full-text]
61. Sentinel node identification in clinical stage Ia non-small cell lung cancer by a combined single photon emission computed tomography/computed tomography system.
    J Thorac Cardiovasc Surg, 134(1): 182-7. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.